Form 4: Elevation Oncology CFO Tammy Furlong Reports Stock Transactions
SEC Form 4 Filing
Tammy Furlong, CFO of Elevation Oncology, reports the vesting and subsequent disposal of shares related to restricted stock units.
Summary
- On May 15, 2024, Tammy Furlong, the Chief Financial Officer of Elevation Oncology, engaged in transactions involving the company's common stock.
- Furlong vested 300 shares from restricted stock units (RSUs).
- She then disposed of 100 shares to cover tax obligations at a price of $3.73 per share.
- Following these transactions, Furlong directly owns 997 shares of common stock and 3,300 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It's a standard practice for publicly traded companies.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they represent a small portion of the overall outstanding shares.
Key Dates
| Date | Description |
|---|---|
| February 15, 2024 | 25% of the RSUs vested. |
| May 15, 2024 | Date of the reported transactions: vesting of 300 RSUs and disposal of 100 shares for tax obligations. |
| May 17, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.